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The purpose of this experiment was to investigate the visible imaging of gastric adenocarcinoma cells in vitro by
targeting tumor-associated glycoprotein 72 (TAG-72) with near-infrared quantum dots (QDs). QDs with an emission
wavelength of about 550 to 780 nm were conjugated to CC49 monoclonal antibodies against TAG-72, resulting in a
probe named as CC49-QDs. A gastric adenocarcinoma cell line (MGC80-3) expressing high levels of TAG-72 was
cultured for fluorescence imaging, and a gastric epithelial cell line (GES-1) was used for the negative control group.
Transmission electron microscopy indicated that the average diameter of CC49-QDs was 0.2 nm higher compared with
that of the primary QDs. Also, fluorescence spectrum analysis indicated that the CC49-QDs did not have different
optical properties compared to the primary QDs. Immunohistochemical examination and in vitro fluorescence imaging
of the tumors showed that the CC49-QDs probe could bind TAG-72 expressed on MGC80-3 cells.
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Gastric cancer has ranked as one of the most frequent
tumors in the world with approximately 989,000 new
cases and 738,000 deaths per year [1]. The most import-
ant part in surgery is to correctly define the boundary of
the tumor and precisely determine the regions for surgi-
cal resection in order to improve survival rate and qual-
ity of life. However, visualized methods to detect the
tumor cells during surgery are currently not available.
Both D1 lymphadenectomy proposed by Western
researchers and D2 lymphadenectomy proposed by
Japanese researchers cannot achieve high specificity [2].
Clinical doctors could only estimate the tumor boundary
for surgical resection by experience and the changes of
the tumor tissue texture, which results in a high failure
rate of complete removal of gastric cancer and greatly
affects the survival rate of the patients. Therefore, devel-
opment of methods for real-time identification of tumor
cells and metastasized lymph nodes during surgery and
establishment of tailored surgical resection for each* Correspondence: surgeonpeng@foxmail.com
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in any medium, provided the original work is pindividual are one of the key factors in improving the
survival rate for gastric cancer.
Recently, quantum dots (QDs) were developed on the
interdisciplinary advancement of nanotechnology, chem-
istry, and optics. The unique optical properties of QDs
have shown promising prospects in the tumor tissue and
metastasized lymph node clearance for cancer patients
[3]. Compared with traditional organic dyes, inorganic
semiconductor QDs exhibit more advantages on light
absorption, bright fluorescence, narrow symmetric emis-
sion bands, high photostability, and size-tunable optical
properties and are considered to be valuable fluorescent
probes for tissue imaging. Particularly, people pay close
attention to near-infrared (NIR) QDs for visible in vivo
tissue imaging due to their reduced absorbance and scat-
tering in biological tissues within the NIR region, as well
as the strong penetration in human tissues. The unique
optical properties and the ease of modification of QDs by
some bioactive materials make these nanoparticles as
highly promising fluorescent labels for in vivo biological
applications [4,5]. Currently, fluorescent probes have been
developed by conjugating QDs with target molecules (e.g.,
antibodies and peptides) and have been used for in vivo
visualization of cancer cells [6], sentinel lymph noden Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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More important, new synthetic techniques of QDs bio-
logically functionalized QDs with excellent biological com-
patibility and water solubility, which pave the way for the
application of tissue imaging in vivo [10].
A common limitation of the QDs’ use in tissue im-
aging in vivo was their potential toxicity. Some re-
searchers claimed that the oxidation of Cd2+ on the QD
surface and subsequent Cd2+ release may induce poten-
tial cytotoxicity [11]. However, many authoritative stud-
ies showed that there was no significant influence on
cell viability, morphology, function, or development in
the use of QDs [12,13]. Besides, no obvious toxicity evi-
dence was obtained during in vivo imaging [7,14-16]. In
our previous experiments, CdTe quantum dots were
proved not having acute toxicity to rats when they were
injected in the subserosa layer of the rats’ stomach [17].
Many studies have demonstrated that 75% of gastric
adenocarcinomas highly express tumor-associated glyco-
protein 72 (TAG-72) [18]. Specific targeting of TAG-72
by CC49 antibodies has been widely used for the treat-
ment of gastric cancer [19-21]. Therefore, visual imaging
by targeting TAG-72 has broad applicability for gastric
cancer detection. The authors of this research attached
CC49 monoclonal antibodies to QDs with a maximal
emission wavelength of 710 nm to produce a probe
designated as CC49-QDs and reported the use of CC49-
QDs as fluorescent probes for imaging the human gas-
tric adenocarcinoma cell line MGC80-3.
Methods
Main equipment, reagents, and cell lines
Cadmium chloride (CdCl2), 3-mercaptopropionic acid
(MPA), and sodium borohydride (NaBH4) were pur-
chased from Acros Organics (Geel, Belgium). Tellurium
powder was purchased from Sigma-Aldrich (St. Louis,
MO, USA). N-(3-Dimethylaminopropyl)-N-ethylcarbo-
diimide hydrochloride (EDC) and N-hydroxysuccinimide
(NHS) were supplied by Shanghai Medpep Co., Ltd.
(Shanghai, China). The gastric cancer cell line MGC80-3
was supplied by Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences (Shanghai,
China). The human gastric epithelial cell line GES-1 was
purchased from Beijing Institute for Cancer Research
(Beijing, China). CC49 monoclonal antibody and sec-
ondary antibody were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The fluorescence
images of cells were obtained with a Nikon microscope
(NIKON 80i, Tokyo, Japan) which was equipped with a
high-definition CCD camera, a 160-W Hg excitation
lamp, and three filters (λex 380 nm/λem 420 nm, λex 490
nm/λem 520 nm, and λex 560 nm/λem 590 nm). Agilent
1200 and gel permeation column was purchased from
Agilent (Santa Clara, CA, USA).Synthesis of CdTe QDs
The synthesis of CdTe QDs has been described in detail
elsewhere [22]. Briefly, 100 mg sodium borohydride was
used to react with 127 mg (1 mmol) tellurium in 20 ml
of distilled water under an ice water bath condition to
prepare sodium hydrogen telluride (NaHTe). With con-
tinuous steady nitrogen flow and vigorous stirring, a
clear and purple NaHTe solution was successfully pro-
duced. To ensure that the mole ratio of Cd2+ to MPA
was 1:1.8, 366.6 mg (2 mmol) CdCl2 and 382.1 mg (3.6
mmol) MPA were dissolved in 100 ml of water followed
by adjustment of pH to 9.0 in the ice water bath. Then,
1 ml of oxygen-free solution containing fresh NaHTe,
cooled to 0°C, was added to 20 ml of the above CdCl2-
MPA solution and vigorously stirred. Finally, a Teflon-
lined stainless steel autoclave with a volume of 9 ml of
precursor solution was placed in a drying oven at 185°C.
The precipitation products were washed with ethanol
three times and then put into a vacuum drying oven at
40°C. Primary QDs were thus obtained. The photolumi-
nescence (PL) quantum yield (QY) of CdTe QDs was
estimated by comparison with Rhodamine 6G in ethanol
at room temperature, assuming its PL QY as 45% [22]. X-
ray diffraction (XRD) patterns of CdTe QDs were taken on
a Rigaku D/MAX-IIA diffractometer (Shibuya-ku, Japan)
using Cu KαR radiation [21].
Synthesis of CC49-QDs
Preparation of CC49-QDs antibody (Ab) probes was
performed according to instructions of the QD Antibody
Conjugation Kits [23]. Briefly, 13.5 μl of EDC and 13.5
μl of NHS were mixed with a 50-μl CdTe QD solution
and shaken for 0.5 h at room temperature. Then, 594 μl
of CC49 monoclonal antibodies was added, resulting in
a CdTe to antibody ratio of 1:4. Another 2 h was needed
for the reaction at room temperature followed by centri-
fugation. The centrifugation was done four times using a
100K ultra filter at 5,000 rpm for 15 min. Each time,
liquids at the lower strata were discarded, and the super-
natant products were diluted by 200 μl of phosphate-
buffered saline (PBS) before subsequent centrifugation.
The final product was diluted with PBS (pH 7.4) and
stored in a refrigerator at 4°C.
QD and CC49-QDs electron microscopy and spectrum
analysis
The prepared primary QDs and CC49-QDs were separ-
ately diluted in deionized water, and several drops were
dropped onto two pieces of carbon films supported by a
copper mesh. When the water volatilized, they were put
under the electron microscope adjusted to a 200-V stem
mode for observation. Diluted QDs and CC49-QDs were
put under a spectrofluorimeter with a 450-nm excitation
wavelength and a 1-mm slit. The curves of the spectra
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meter of emission light between 550 and 800 nm.
Gel permeation high-performance liquid chromatography
The CC49 and CC49-QDs were monitored by high-
performance liquid chromatography (HPLC) gel filtration.
Samples were injected onto a ZORBAX GF-450 (9.5 ×
250, 6-μm size, Agilent) exclusion column connected in a
series with 67 mM phosphate and 100 mM KCl buffer
(pH 6.8) as a mobile phase at a flow rate of 1 ml/min. The
absorption was monitored at 280 nm [24,25].
Immunohistochemical detection of TAG-72
One milliliter of MGC80-3 cells and GES-1 at a concen-
tration of 2 × 104 cells/ml were separately seeded into
each well of a 24-well plate containing a glass cover slip.
After 24 h of culture, the cells were fixed with 4% para-
formaldehyde for 20 min. Streptavidin peroxidase (SP)
immunohistochemical staining was performed according
to instructions of the Sunhis-H kits. Briefly, the cover
slips were incubated with 3% H2O2 deionized water for
10 min, and washed with PBS two times (each for 3
min). Consequently, the cover slips were incubated with
protein blocking working liquid at room temperature for
5 min before the CC49 monoclonal antibody (1:100) was
added. After incubation overnight at 4°C, the cover slips
were washed with PBS three times (each for 3 min), and
then biotin-labeled goat antimouse immunoglobulin G
was added. After 10 min, PBS was also used to wash the
cover slips for three times (each for 5 min). Then, the
streptavidin conjugate of horseradish peroxidase was
added for incubation for another 10 min. Finally,
diaminobenzidine was added for color development. The
negative control group was prepared by adding PBS in-
stead of the primary antibody. Brown-yellow granules
that appeared in the cells indicated a positive result [26].
In vitro immunofluorescence
MGC80-3 cells and GES-1 at a concentration of 5 × 104
cells/ml were seeded separately onto four 35-mm culture
dishes with glass bottoms (1 ml in each dish). The four
35-mm culture dishes of MGC80-3 were marked A, B,
C, and D, while those of the GES-1 group were marked
E, F, G, and H. After 24 h of culture, the cells were
washed with PBS twice. The experimental dishes B and
F were added with 100 μl of CC49-QDs Ab probe (337.5
nmol). The negative control dishes A and E were added
100 μl of QDs (337.5 nmol) for the purpose of
insteading of the CC49-QDs Ab probe. The cells in the
four dishes described above were incubated for 1 h at
37°C and then washed with PBS three times. The com-
petitive group dishes C and G were added to 200 μl of
CC49 monoclonal antibody (1 μg/ml) for 2 h of
blocking. Subsequently, the cells were washed with PBStwice, and then an equimolar amount of CC49-QDs Ab
probe was added to the experimental dishes. To the
positive control dishes D and H, 100 μl of CC49 mono-
clonal antibody (1 μg/ml) was added for 2 h of blocking.
After washing three times (each for 3 min), fluorescent
secondary antibody (goat against mouse IgG and conju-
gated to fluorescein isothiocyanate, 1:100) was added for
another 30 min of incubation. 4′,6-Diamidino-2-pheny-
lindole (DAPI) was used to label the cell nucleus before
imaging with a fluorescence microscope.
In the fluorescence imaging of the cancer cells, the cell
nucleus stained with DAPI (A1/B1/C1/D1 in Figure 1
and E1/F1/G1/H1 in Figure 2) was observed under the
UV mode in which the excitation wavelength was 330 to
380 nm and the emission wavelength was 400 to 420
nm. MGC80-3 cells labeled with QDs (A2 in Figure 1)
and CC49-QDS (B2 and C2 in Figure 1) were ob-
served under the G-2A mode in which the excitation
wavelength was 510 to 560 nm and the emission
wavelength was 575 to 590 nm. GES-1 cells labeled
with QDs (E2 in Figure 2) and CC49-QDS (F2 and
G2 in Figure 2) were observed under the same mode.
MGC80-3 cells (D2 in Figure 1) and GES-1 cells (H2
in Figure 2) labeled with fluorescent secondary anti-
body were imaged under the FITC mode in which
the excitation wavelength was 465 to 490 nm and the
emission wavelength was 505 to 520 nm. All the ex-
periments were repeated three times.
Results and discussion
Synthesis of the QDs and CC49-QDs
In this experiment, near-infrared water-soluble CdTe
QDs (PL QY ≈ 41.6%) were synthesized by a hydrother-
mal route and were then characterized by XRD as shown
in Figure 3. It is well known that the CdTe QDs
belonged to a kind of core-shell CdTe/CdS structure.
The XRD pattern showed that positions of CdTe QDs
were intermediate between the values of cubic CdTe and
CdS phases.
The electron microscope images (Figure 4) of QDs
and CC49-QDs were obtained by transmission electron
microscopy under the stem mode (200 V). The scale
plate in the electron microscope system was used to
measure all the QDs in a single visual field to get their
average diameter and standard deviation. Then, it is the
same for CC49-QDs. The images show that the average
diameters of QDs and CC49-QDs were 3.5 ± 0.30 nm
(Figure 4A) and 3.7 ± 0.31 nm (Figure 4B), respectively.
With the ordinate denoting light intensity and the
abscissa denoting wavelength, the spectrum curves for
QDs and CC49-QDs were drawn. As shown in Figure 5,
the emission wavelengths of primary QDs were between
580 and 800 nm, and the peak appeared around 680 nm
(Figure 5A). The wavelengths of the CC49-QDs emission
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appeared around 710 nm (Figure 5B). Also, the intensity
of the CC49-QDs decreased about 75% as compared
with that of the primary QDs, which may be caused by
the loss of QDs during the centrifugation or the quench
by CC49. Even so, the light is still much stronger than
that of the organic dyes (Figure 1).
In the medical surgery of gastric cancer, determining
the precise boundary of the tumors for individual surgi-
cal resection is the key to improve the survival rate of
cancer patients. Traditional methods (e.g., computed
tomography and magnetic resonance imaging) can pro-
vide good imaging in the detection of tumors but are
not suitable for visible detection of tumor cells during
surgery. Cancer cell imaging provides us a new way to
develop the individual treatment for gastric cancer.
In tumor cell imaging, the ideal method should be
sensitive, accurate, rapid, noninvasive, nonradioactive,Figure 1 In vitro labeling of MGC80-3 cells with CC49-QDs Ab probe a
DAPI. (A2) MGC80-3 cells labeled with QDs. (B2) MGC80-3 cells labeled with
with free CC49. (D2) MGC80-3 cells labeled with fluorescent secondary anti
C2, D1 and D2, respectively.and potentially useful in surgery. Previous cancer cell
imaging usually involves a preoperative injection of a
radioactive colloid tracer (e.g., 99mTc sulfur colloid)
followed by an intraoperative injection of a visible blue
dye (e.g., isosulfan blue). However, these staining mate-
rials have deficits in imaging, such as poor tissue con-
trast and difficult detection in deep, dark anatomical
regions. As to radioactive isotopes, the high radioactivity
of the primary injection site can interfere with intra-
operative in vivo detection of nearby lymph nodes
[27,28]. For QDs, their unique optical properties have
been mentioned earlier. More important, QDs can be
easily modified and conjugated with other biological
molecules. Conjugated QDs with good photochemical
stability can easily penetrate tumor angiogenesis and
access cancer cells. As a result, they possess unique
advantages in the surgical treatment of individual cancer
patients.nd primary QDs. (A1/B1/C1/D1) The cell nucleus was stained with
CC49-QDs. (C2) MGC80-3 cells labeled with CC49-QDs after blocked
body. A3/B3/C3/D3 were merged with A1 and A2, B1 and B2, C1 and
Figure 3 Powder X-ray diffraction pattern of hydrothermally prepared CdTe QDs (λcm = 600 nm). The line spectra show the cubic CdTe
and CdS reflections with their relative intensities.
Figure 2 In vitro labeling of GES-1 cells with CC49-QDs Ab probe and primary QDs. (E1/F1/G1/H1) The cell nucleus was stained with DAPI.
(E2) GES-1 cells labeled with QDs. (F2) GES-1 cells labeled with CC49-QDs. (G2) GES-1 cells labeled with CC49-QDs after blocked with free CC49.
(H2) GES-1 cells labeled with fluorescent secondary antibody. E3/F3/G3/H3 were merged with E1 and E2, F1 and F2, G1 and G2, H1 and
H2, respectively.
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Figure 5 Spectrum analysis. (A) The primary CdTe QD spectrum analysis
Figure 4 Physical properties of near-infrared quantum dots. (A)
Transmission electron microscope image of QDs. (B) Transmission
electron microscope image of CC49-QDs.
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In the experiment, the formation of QD bioconjugates
was confirmed by HPLC size-exclusion chromatography.
As the species with higher molecular weights are eluted
in shorter retention times, the HPLC peaks observed at
retention time 9.65 min were attributed to free CC49
(Figure 6A,B). The molecular weight of the CC49 anti-
body is 150 kDa. After conjugation, being shifted to a
higher molecular weight, the peaks can be observed at
6.91 min, as expected for the attachment of QDs to
CC49 (Figure 6A).Immunohistochemical detection of TAG-72
Immunohistochemical staining demonstrated that the
CC49 monoclonal antibodies bound to TAG-72 of the
MGC80-3 cells. As shown in Figure 7, positive staining
(brown stain) was observed for the MGC80-3 cells of
the CC49 antibody group (Figure 7A), as expected, indi-
cating that TAG-72 is highly expressed in these tumorcurve. (B) The CC49-QDs spectrum analysis curve.
Figure 6 HPLC elution curves for (A) CC49-QDs and (B) free CC49. The retention times of CC49-QDs and free CC49 were about 6.91 and 9.65
min, respectively.
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TAG-72 expression (Figure 7B). Similarly, after incuba-
tion, the two negative control groups of the MGC80-3
cell line (Figure 7C) and the GES-1 cell line (Figure 7D)
were observed to have no positive stain.
TAG-72 is a membrane protein complex that is
overexpressed in a number of cancers, such as colonic
adenocarcinoma, invasive ductal carcinoma of the
breast, nonsmall cell lung carcinoma, epithelial ovarian
carcinoma, as well as pancreatic and gastric esophageal
cancers [29], with only trace levels found in histological
sections of normal tissues [30,31]. In previous studies,
131I-labeled MAb B72.3 has demonstrated prolonged
binding to human colon carcinoma xenografts, allowing
in situ radioimmunodetection in the nude mouse model
[32-35]. In this experiment, one of these second-
generation MAb B72.3, CC49, was used to develop a
probe to detect the TAG-72 of the gastric cancer cellFigure 7 Immunohistochemical examination of TAG-72 expression. Ex
and GES-1 (B). Control group (the primary antibody was replaced by PBS): theline MGC80-3. Positive immunohistochemical staining
(brown stain) was observed for the CC49 antibody, as
expected, demonstrating that the CC49 antibody bound
to MGC80-3 tumor cells, which indicated that TAG-72
is highly expressed in this tumor, while normal gastric
epithelial cells (negative control) show no TAG-72 ex-
pression (Figure 7B).
CC49-QDs Ab probe specifically binds to TAG-72 of
MGC80-3 cells in vitro
Streptavidin peroxidase immunohistochemical analysis
indicated that TAG-72 was expressed on the membrane
and in the cytoplasm of MGC80-3 cells (Figure 7).
Direct immunofluorescence examination with the CC49-
QDs Ab probe showed that red fluorescence was present
on the membrane of MGC80-3 cells in the experimental
group (group B in Figure 1). In contrast, red fluores-
cence cannot be observed in the other groups ofperimental group: the SP immunohistochemical staining of MGC80-3 (A)
SP immunohistochemical staining of MGC80-3 (C) and GES-1 (D).
Zhang et al. Nanoscale Research Letters 2013, 8:294 Page 8 of 9
http://www.nanoscalereslett.com/content/8/1/294MGC80-3 cells (groups A and C in Figure 1) and GES-1
cell groups (groups E to G in Figure 2). These results
demonstrated that the CC49-QDs Ab probe can recognize
and bind efficiently to the unblocked TAG-72 of MGC80-3
cells. In contrast, MGC80-3 cells, of which TAG-72 had
been blocked by the CC49 antibody (C in Figure 1) and
GES-1 cells, cannot recognize and bind efficiently.
By adding QDs to CC49 antibodies, we generated a
fluorescence probe directed against TAG-72 in gastric
cancer cells for the first time. These alterations of the
CC49 molecule did not affect the antigen-antibody
reaction of CC49 and TAG-72. Also, in this experi-
ment, the in vitro binding studies showed the specific
binding between the CC49-QDs and the TAG-72
antigen on the MGC80-3 cells. The possibility of
nonspecific binding between free QDs and MGC80-3
cells was excluded by the finding that negligible fluores-
cence was detected from the cells incubated with free QDs.
Furthermore, excessive CC49 antibody successfully blocked
the binding of CC49-QDs to the MGC80-3 cells, indicating
that the binding was mediated through TAG-72. For the
GES-1 cell line, neither in the CC49-QDs group nor in the
free QD group could visible fluorescence be observed be-
cause of the absence of TAG-72.
The experiment has demonstrated the imaging of gas-
tric carcinoma cells and the immunoassay of TAG-72
with near-infrared quantum dots. The optical properties
and stability of these QDs and CC49-QDs have been
studied. Due to the advantage of near-infrared QDs and
CC49-QDs as cell imaging tools, the bioconjugation and
immunofluorescent images were studied. The cell im-
ages indicate that they have a very good signal in a
biotin-streptavidin labeling system. Furthermore, com-
pared to QDs, the CC49-QDs could specifically bind to
the TAG-72 of gastric cancer cells. So, the experiment
demonstrates that the CC49-QDs could be another
probe for gastric tumor cell detection.
Conclusions
In conclusion, by the addition of CC49, we generated a
specific QD molecule that not only has the potential to
bind tumor cell in vitro but also could be used in a long-
term therapeutic regimen to possibly alter individual
cancer treatment. Further preclinical studies utilizing
our CC49-QDs fusion construct, addressing the short-
term and long-term capabilities, will be performed to de-
velop regimens for improved gastric cancer treatment.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YPZ wrote the paper and finished the main work of the experiment,
including QD and CC49-QDs electron microscopy and spectrum analysis, gel
permeation high-performance liquid chromatography, immunohistochemical
detection of TAG-72, and in vitro immunofluorescence. PS and WLYconceived of the idea and provided some useful suggestion. XRZ and CSS
finished the former parts of the experiment such as the synthesis of CdTe
QDs and CC49-QDs. All authors read and approved the final manuscript.
Acknowledgements
This study was supported by the National Nature Science Foundation of
China (no. 20874015) and the Science and Technology Commission Nano
Special Fund of the Shanghai Municipality (no. 1052nm03802).
Author details
1Department of General Surgery, Huashan Hospital, Fudan University,
Shanghai 200040, China. 2State Key Laboratory of Molecular Engineering of
Polymers and Department of Macromolecular Science, Fudan University,
Shanghai 200433, China.
Received: 7 April 2013 Accepted: 16 June 2013
Published: 22 June 2013
References
1. Gómez-Martin C, Sánchez A, Irigoyen A, Llorente B, Pérez B, Serrano R,
Safont MJ, Falcó E, Lacasta A, Reboredo M, Aparicio J, Dueñas R, Muñoz ML,
Regueiro P, Sanchez-Viñes E, López RL: Incidence of hand-foot syndrome
with capecitabine in combination with chemotherapy as first-line
treatment in patients with advanced and/or metastatic gastric cancer
suitable for treatment with a fluoropyrimidine-based regimen. Clin Transl
Oncol 2012, 14(9):689–697.
2. Pericleous P, Gazouli M, Lyberopoulou A, Rizos S, Nikiteas N, Efstathopoulos
EP: Quantum dots hold promise for early cancer imaging and detection.
Int J Cancer 2012, 131:519–528.
3. Chen C, Peng J, Sun SR, Peng CW, Li Y, Pang DW: Tapping the potential of
quantum dots for personalized oncology: current status and future
perspectives. Nanomedicine (Lond) 2012, 7(3):411–428.
4. Xue B, Deng DW, Cao J, Liu F, Li X, Akers W, Achilefu S, Gu YQ: Synthesis of
NAC capped near infrared-emitting CdTeS alloyed quantum dots and
application for in vivo early tumor imaging. Dalton Trans 2012,
41(16):4935–4947.
5. Yang K, Cao YA, Shi C, Li ZG, Zhang FJ, Yang J, Zhao C: Quantum dot-
based visual in vivo imaging for oral squamous cell carcinoma in mice.
Oral Oncol 2010, 46(12):864–868.
6. Frangioni JV, Kim SW, Ohnishi S, Kim S, Bawendi MG: Sentinel lymph node
mapping with type-II quantum dots. Methods Mol Biol 2007, 374:147–159.
7. van Vlerken LE, Amiji MM: Multi-functional polymeric nanoparticles for
tumour-targeted drug delivery. Expert Opin Drug Deliv 2006, 3(2):205–216.
8. Ballou B, Ernst LA, Andreko S, Harper T, Fitzpatrick JA, Waggoner AS,
Bruchez MP: Sentinel lymph node imaging using quantum dots in mouse
tumor models. Bioconjug Chem 2007, 18(2):389–396.
9. Gaponik N, Talapin DV, Rogach AL, Hoppe K, Shevchenko EV, Kornowski A,
Eychmuller A, Weller H: Thiol-capping of CdTe nanocrystals: an alternative
to organometallic synthetic routes. J Phys Chem B 2002, 106:7177–7185.
10. Derfus AM, Chan WCW, Bhatia SN: Probing the cytotoxicity of
semiconductor quantum dots. Nano Lett 2004, 4:11–18.
11. Gao X, Cui Y, Levenson RM, Chung LW, Nie S: In vivo cancer targeting and
imaging with semiconductor quantum dots. Nat Biotechnol 2004, 22:969–976.
12. Voura EB, Jaiswal JK, Mattoussi H, Simon SM: Tracking metastatic tumor
cell extravasation with quantum dot nanocrystals and fluorescence
emission-scanning microscopy. Nat Med 2004, 10:993–998.
13. Kim SW, Kim S, Tracy JB, Jasanoff A, Bawendi MG: Phosphine oxide polymer
for water-soluble nanoparticles. J Am Chem Soc 2005, 127:4556–4557.
14. Soltesz EG, Kim S, Laurence RG, DeGrand AM, Parungo CP, Dor DM, Cohn
LH, Bawendi MG, Frangioni JV, Mihaljevic T: Intraoperative sentinel lymph
node mapping of the lung using near-infrared fluorescent quantum
dots. Ann Thorac Surg 2005, 79:269–277.
15. Kim S, Lim YT, Soltesz EG, De Grand AM, Lee J, Nakayama A, Parker JA,
Mihaljevic T, Laurence RG, Dor DM, Cohn LH, Bawendi MG, Frangioni JV:
Near-infrared fluorescent type II quantum dots for sentinel lymph node
mapping. Nat Biotechnol 2004, 22:93–97.
16. Li P, Sun P, Yang W, Zhang X: Real-time mapping of rat stomach lymph
nodes by quantum dots. Scand J Gastroenterol 2012, 47:454–460.
17. Chen L, Wang Y, Liu X, Dou S, Liu G, Hnatowich DJ, Rusckowski M: A new
TAG-72 cancer marker peptide identified by phage display. Cancer Lett
2008, 272(1):122–132.
Zhang et al. Nanoscale Research Letters 2013, 8:294 Page 9 of 9
http://www.nanoscalereslett.com/content/8/1/29418. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D:
Analysis of a human tumor-associated glycoprotein (TAG-72) identified
by monoclonal antibody B72.3. Cancer Res 1986, 46(2):850–857.
19. Muraro R, Kuroki M, Wunderlich D, Poole DJ, Colcher D, Thor A, Greiner JW,
Simpson JF, Molinolo A, Noguchi P, Schlom J: Generation and
characterization of B72.3 second generation monoclonal antibodies
reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res
1988, 48(16):4588–4596.
20. Sheer DG, Schlom J, Cooper HL: Purification and composition of the
human tumor-associated glycoprotein (TAG-72) defined by monoclonal
antibodies CC49 and B72.3. Cancer Res 1988, 48(23):6811–6818.
21. Guo J, Yang W, Wang C: Systematic study of the photoluminescence
dependence of thiol-capped CdTe nanocrystals on the reaction
conditions. J Phys Chem B 2005, 109(37):17467–17473.
22. Demasa JN, Crosby GA: The measurement of photoluminescence
quantum yields. J Phys Chem 1971, 75(8):991–1024.
23. Hu M, Yan J, He Y, Lu H, Weng L, Song S, Fan C, Wang L: Ultrasensitive,
multiplexed detection of cancer biomarkers directly in serum by using a
quantum dot-based microfluidic protein chip. ACS Nano 2010, 4(1):488–494.
24. Wittel UA, Jain M, Goel A, Baranowska-Kortylewicz J, Kurizaki T, Chauhan SC,
Agrawal DK, Colcher D, Batra SK: Engineering and characterization of a
divalent single-chain Fv angiotensin II fusion construct of the monoclonal
antibody CC49. Biochem Biophys Res Commun 2005, 329(1):168–176.
25. Tian J, Liu R, Zhao Y, Peng Y, Hong X, Xu Q, Zhao S: Synthesis of CdTe/
CdS/ZnS quantum dots and their application in imaging of
hepatocellular carcinoma cells and immunoassay for alpha fetoprotein.
Nanotechnology 2010, 21(30):305101.
26. Yang K, Zhang FJ, Tang H, Zhao C, Cao YA, Lv XQ, Chen D, Li YD: In-vivo
imaging of oral squamous cell carcinoma by EGFR monoclonal antibody
conjugated near-infrared quantum dots in mice. Int J Nanomedicine 2011,
6:1739–1745.
27. Yokota T, Ishiyama S, Saito T, Teshima S, Shimotsuma M, Yamauchi H:
Treatment strategy of limited surgery in the treatment guidelines for
gastric cancer in Japan. Lancet Oncol 2003, 4(7):423–428.
28. Allum WH, Griffin SM, Watson A, Colin-Jones D, on behalf of the Association
of Upper Gastrointestinal Surgeons of Great Britain and Ireland, the British
Society of Gastroenterology, and the British Association of Surgical
Oncology: Guidelines for the management of oesophageal and gastric
cancer. Gut 2002, 50(Suppl 5):v1–v23.
29. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J: Distribution of
oncofetal antigen tumor-associated glycoprotein-72 defined by
monoclonal antibody B72.3. Cancer Res 1986, 46(6):3118–3124.
30. Stramignoni D, Bowen R, Atkinson BF, Schlom J: Differential reactivity of
monoclonal antibodies with human colon adenocarcinomas and
adenomas. Int J Cancer 1982, 31(5):543–552.
31. Nuti M, Teramoto YA, Mariani-Costantini R, Hand PH, Colcher D, Schlom J: A
monoclonal antibody (B72.3) defines patterns of distribution of a novel
tumor-associated antigen in human mammary carcinoma cell
populations. Int J Cancer 1982, 29(5):539–545.
32. Colcher D, Zalutsky M, Kaplan W, Kufe D, Austin F, Schlom J:
Radiolocalization of human mammary tumors in athymic mice by a
monoclonal antibody. Cancer Res 1983, 43(2):736–742.
33. Seldom J, Greiner J, Horan Hand P, Colcher D, Inghirami G, Weeks M, Pestka
S, Fisher PB, Noguchi P, Kufe D: Monoclonal antibodies to breast cancer-
associated antigens as potential reagents in the management of breast
cancer. Cancer (Phila) 1984, 54(11 Suppl):2777–2794.
34. Keenan AM, Colcher D, Larson SM, Schlom J: Radioimmunoscintigraphy of
human colon cancer xenografts in mice with radioiodinated monoclonal
antibody B72.3. J Nucl Med 1984, 25(11):1197–1203.
35. Coleher D, Keenan AM, Larson SM, Schlom J: Prolonged binding of a
radiolabeled monoclonal antibody (B72.3) used for the in situ
radioimmunodetection of human colon carcinoma xenografts.
Cancer Res 1984, 44(12 Pt 1):5744–5751.
doi:10.1186/1556-276X-8-294
Cite this article as: Zhang et al.: Synthesis of CdTe quantum dot-
conjugated CC49 and their application for in vitro imaging of gastric
adenocarcinoma cells. Nanoscale Research Letters 2013 8:294.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
